Literature DB >> 7010207

Double-blind, triple-crossover trial of low doses of oral physostigmine in inherited ataxias.

R A Kark, M M Budelli, R Wachsner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7010207     DOI： 10.1212/wnl.31.3.288

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

1.  Cerebellar Ataxia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 2.  Pharmacological treatments of cerebellar ataxia.

Authors:  Masafumi Ogawa
Journal:  Cerebellum       Date:  2004       Impact factor: 3.847

Review 3.  Emerging therapies in Friedreich's ataxia.

Authors:  Tanya V Aranca; Tracy M Jones; Jessica D Shaw; Joseph S Staffetti; Tetsuo Ashizawa; Sheng-Han Kuo; Brent L Fogel; George R Wilmot; Susan L Perlman; Chiadi U Onyike; Sarah H Ying; Theresa A Zesiewicz
Journal:  Neurodegener Dis Manag       Date:  2016

Review 4.  Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders.

Authors:  Maryka Quik; James T Boyd; Tanuja Bordia; Xiomara Perez
Journal:  Nicotine Tob Res       Date:  2019-02-18       Impact factor: 4.244

5.  Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Authors:  Theresa A Zesiewicz; George Wilmot; Sheng-Han Kuo; Susan Perlman; Patricia E Greenstein; Sarah H Ying; Tetsuo Ashizawa; S H Subramony; Jeremy D Schmahmann; K P Figueroa; Hidehiro Mizusawa; Ludger Schöls; Jessica D Shaw; Richard M Dubinsky; Melissa J Armstrong; Gary S Gronseth; Kelly L Sullivan
Journal:  Neurology       Date:  2018-02-09       Impact factor: 9.910

6.  Therapeutic interventions in the primary hereditary ataxias.

Authors:  Gonzalo J Revuelta; George R Wilmot
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

7.  Pharmacokinetics of physostigmine in man following a single application of a transdermal system.

Authors:  K Walter; M Müller; M F Barkworth; A V Nieciecki; F Stanislaus
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

8.  Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia.

Authors:  L Wecker; M E Engberg; R M Philpot; C S Lambert; C W Kang; J C Antilla; P C Bickford; C E Hudson; T A Zesiewicz; Peter P Rowell
Journal:  Neuropharmacology       Date:  2013-05-24       Impact factor: 5.250

Review 9.  Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.

Authors:  Maryka Quik; Danhui Zhang; Xiomara A Perez; Tanuja Bordia
Journal:  Pharmacol Ther       Date:  2014-05-14       Impact factor: 12.310
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.